Pasithea Therapeutics Corp.(KTTA)Earnings, Financials & Key Ratios
KTTA•NASDAQ
$0.84
$19M mkt cap·Price updated May 7, 2026
AboutPasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.Show more
- Revenue$0
- EBITDA-$14M+11.3%
- Net Income-$14M+12.9%
- EPS (Diluted)-12.69+2.5%
- ROE-72.83%-50.3%
- ROIC-142.41%-1.4%
KTTA Key Insights
Pasithea Therapeutics Corp. (KTTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 10.6% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KTTA Price & Volume
Pasithea Therapeutics Corp. (KTTA) stock price & volume — 10-year historical chart
Loading chart...
KTTA Growth Metrics
Pasithea Therapeutics Corp. (KTTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.28%
Return on Capital
10 Years-38.13%
5 Years-38.13%
3 Years-49.4%
Last Year-74.17%
KTTA Peer Comparison
Pasithea Therapeutics Corp. (KTTA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 902.25M | 9.39 | -3.05 | -335.93% | ||||
 ATAI | 964.15M | 4.01 | -4.31 | -1.91% | -51.09% | -96.43% | 0.21 | |
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 NRXP | 84.71M | 3.06 | -2.28 | -157.28% | ||||
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ALTO | 350.91M | 4.54 | 28.38 | -4.9% | 1.45% | 6% | 0.40 |
Compare KTTA vs Peers
Pasithea Therapeutics Corp. (KTTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KTTA Income Statement
Pasithea Therapeutics Corp. (KTTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 15.06K | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | -100% | - | - | - |
| Cost of Goods Sold | 0 | 17.27K | 5.09K | 0 | 0 | 343.8K |
| COGS % of Revenue | - | 114.69% | - | - | - | - |
| Gross Profit | 0▲ 0% | -2.21K▲ 0% | -5.09K▼ 130.2% | 0▲ 100.0% | 0▲ 0% | -343.8K▲ 0% |
| Gross Margin % | - | -14.69% | - | - | - | - |
| Gross Profit Growth % | - | - | -130.19% | 100% | - | - |
| Operating Expenses | 61.48K | 4.51M | 12.58M | 15.98M | 14.25M | 13.52M |
| OpEx % of Revenue | - | 29911.03% | - | - | - | - |
| Selling, General & Admin | 0 | 0 | 9.92M | 0 | 7.05M | 6.77M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 0 | 0 | 2.67M | 8.1M | 7.2M | 6.75M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 61.48K | 4.51M | 0 | 7.88M | 0 | 655 |
| Operating Income | -61.48K▲ 0% | -4.51M▼ 7232.0% | -12.59M▼ 179.3% | -15.98M▼ 26.9% | -14.25M▲ 10.8% | -13.86M▲ 0% |
| Operating Margin % | - | -29925.73% | - | - | - | - |
| Operating Income Growth % | - | -7231.99% | -179.29% | -26.93% | 10.82% | - |
| EBITDA | 0 | -4.51M | -12.58M | -15.33M | -13.6M | -13.19M |
| EBITDA Margin % | - | -29916.57% | - | - | - | - |
| EBITDA Growth % | - | - | -179.27% | -21.83% | 11.28% | 14.83% |
| D&A (Non-Cash Add-back) | 61.48K | 1.38K | 5.09K | 648.45K | 649.03K | 667.25K |
| EBIT | -61.48K | -4.51M | -11.73M | -15.98M | -14.25M | -13.71M |
| Net Interest Income | 0 | -508 | -102 | 0 | 423.18K | 225.55K |
| Interest Income | 0 | 0 | 0 | 0 | 423.18K | 225.55K |
| Interest Expense | 0 | 508 | 102 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 2.33M | 861.09K | 471.61K | 345.38K | 366.21K |
| Pretax Income | -61.48K▲ 0% | -2.17M▼ 3435.6% | -11.73M▼ 439.6% | -15.51M▼ 32.2% | -13.9M▲ 10.3% | -13.49M▲ 0% |
| Pretax Margin % | - | -14430.49% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -61.48K▲ 0% | -2.17M▼ 3435.6% | -13.94M▼ 541.2% | -15.96M▼ 14.5% | -13.9M▲ 12.9% | -13.49M▲ 0% |
| Net Margin % | - | -14430.49% | - | - | - | - |
| Net Income Growth % | - | -3435.56% | -541.19% | -14.53% | 12.89% | 14.46% |
| Net Income (Continuing) | -61.48K | -2.17M | -11.73M | -15.51M | -13.9M | -13.49M |
| Discontinued Operations | 0 | 0 | -2.21M | -453.91K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06▲ 0% | -1.89▼ 3081.8% | -10.34▼ 447.1% | -13.01▼ 25.8% | -12.69▲ 2.5% | -1.81▲ 0% |
| EPS Growth % | - | -3081.82% | -447.09% | -25.82% | 2.46% | 52.28% |
| EPS (Basic) | -0.06 | -1.89 | -10.34 | -12.65 | -12.69 | - |
| Diluted Shares Outstanding | 688.92K | 1.15M | 1.26M | 1.23M | 1.1M | 7.44M |
| Basic Shares Outstanding | 688.92K | 1.15M | 1.26M | 1.26M | 1.1M | 7.44M |
| Dividend Payout Ratio | - | - | - | - | - | - |
KTTA Balance Sheet
Pasithea Therapeutics Corp. (KTTA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 247.96K | 53.3M | 34.08M | 16.69M | 7.37M | 5.53M |
| Cash & Short-Term Investments | 243.65K | 52.97M | 33.09M | 16.33M | 6.92M | 4.12M |
| Cash Only | 243.65K | 52.97M | 33.09M | 16.33M | 6.92M | 4.12M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 40.5K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 426.45K | 104.71K | 142.94K | 120.26K |
| Total Non-Current Assets | 0 | 20.12K | 11.1M | 9.42M | 8.7M | 8.1M |
| Property, Plant & Equipment | 0 | 20.12K | 625.63K | 220.48K | 122.34K | 0 |
| Fixed Asset Turnover | - | 0.75x | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 1.26M | 1.26M | 1.26M | 1.26M |
| Intangible Assets | 0 | 0 | 8.57M | 7.94M | 7.31M | 6.84M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 643.38K | 0 | 0 | 0 |
| Total Assets | 247.96K▲ 0% | 53.32M▲ 21403.9% | 45.18M▼ 15.3% | 26.12M▼ 42.2% | 16.06M▼ 38.5% | 13.63M▲ 0% |
| Asset Turnover | - | 0.00x | - | - | - | 0.00x |
| Asset Growth % | - | 21403.88% | -15.27% | -42.19% | -38.49% | -103.64% |
| Total Current Liabilities | 6.6K | 447.28K | 1.88M | 2.63M | 1.12M | 1.38M |
| Accounts Payable | 6.6K | 0 | 1.48M | 0 | 1.12M | 1.34M |
| Days Payables Outstanding | - | - | 106.15K | - | - | 1.07K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 447.28K | 235.88K | 2.55M | 0 | 39.31K |
| Current Ratio | 37.55x | 119.17x | 18.15x | 6.34x | 6.58x | 6.58x |
| Quick Ratio | 37.55x | 119.17x | 18.15x | 6.34x | 6.58x | 6.58x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 1.45M | 804.21K | 84.37K | 162.17K | 46.87K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 344.02K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 1.45M | 460.19K | 84.37K | 162.17K | 388.09K |
| Total Liabilities | 6.6K | 1.9M | 2.68M | 2.72M | 1.28M | 1.42M |
| Total Debt | 0 | 0 | 504.38K | 81.68K | 0 | 0 |
| Net Debt | -243.65K | -52.97M | -32.58M | -16.25M | -6.92M | -4.12M |
| Debt / Equity | - | - | 0.01x | 0.00x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | 0.31x |
| Interest Coverage | - | -8872.86x | -123421.28x | - | - | - |
| Total Equity | 241.35K▲ 0% | 51.42M▲ 21204.9% | 42.5M▼ 17.4% | 23.4M▼ 44.9% | 14.78M▼ 36.8% | 12.21M▲ 0% |
| Equity Growth % | - | 21204.92% | -17.35% | -44.94% | -36.82% | -109.19% |
| Book Value per Share | 0.35 | 44.70 | 33.67 | 19.08 | 13.49 | 1.64 |
| Total Shareholders' Equity | 241.35K | 51.42M | 42.5M | 23.4M | 14.78M | 12.21M |
| Common Stock | 14.94K | 17.68K | 130 | 104 | 139 | 743 |
| Retained Earnings | -40.98K | -2.21M | -19.36M | -35.32M | -49.58M | -59.9M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -10.56K | -661 | -4.65K | -7.17K | 18.3K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
KTTA Cash Flow Statement
Pasithea Therapeutics Corp. (KTTA) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -38.69K | -3.17M | -13.69M | -13.43M | -13.92M | -13.92M |
| Operating CF Margin % | - | -21073.28% | - | - | - | - |
| Operating CF Growth % | - | -8104.03% | -331.35% | 1.94% | -3.71% | 66.72% |
| Net Income | -40.98K | -2.17M | -11.73M | -15.51M | -13.9M | -13.49M |
| Depreciation & Amortization | 0 | 1.38K | 5.09K | 648.45K | 649.03K | 667.25K |
| Stock-Based Compensation | 0 | 471.25K | 835.06K | 592.27K | 773.69K | 274.59K |
| Deferred Taxes | 0 | -2.33M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 750K | -3.65M | -732.57K | 77.81K | 46.82K |
| Working Capital Changes | 2.29K | 111.23K | 845.35K | 1.57M | -1.52M | 248.11K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 440.68K | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | -21.5K | -2.93M | 399.01K | 0 | 0 |
| Capital Expenditures | 0 | -21.5K | -107.1K | -34.3K | 0 | 0 |
| CapEx % of Revenue | - | 142.76% | - | - | - | - |
| Acquisitions | 0 | 0 | -2.19M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -626.9K | 433.31K | 0 | 0 |
| Cash from Financing | 282.34K | 55.93M | -3.21M | -3.73M | 4.52M | 7.07M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -408.97K |
| Equity Issued (Net) | 282.34K | 50.24M | 0 | -3.73M | 4.52M | 7.48M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -3.73M | 0 | 0 |
| Other Financing | 0 | 5.69M | -3.21M | 0 | 0 | 0 |
| Net Change in Cash | 243.65K▲ 0% | 52.72M▲ 21538.8% | -19.88M▼ 137.7% | -16.76M▲ 15.7% | -9.41M▲ 43.9% | -5.14M▲ 0% |
| Free Cash Flow | -38.69K▲ 0% | -3.2M▼ 8159.4% | -13.8M▼ 331.8% | -13.46M▲ 2.5% | -13.92M▼ 3.4% | -12.26M▲ 0% |
| FCF Margin % | - | -21216.05% | - | - | - | - |
| FCF Growth % | - | -8159.4% | -331.79% | 2.45% | -3.45% | 17.04% |
| FCF per Share | -0.06 | -2.78 | -10.93 | -10.97 | -12.70 | -12.70 |
| FCF Conversion (FCF/Net Income) | 0.63x | 1.46x | 0.98x | 0.84x | 1.00x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
KTTA Key Ratios
Pasithea Therapeutics Corp. (KTTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -8.41% | -29.68% | -48.44% | -72.83% | -97.88% |
| Return on Invested Capital (ROIC) | - | -225.65% | -140.47% | -142.41% | -142.41% |
| Gross Margin | -14.69% | - | - | - | - |
| Net Margin | -14430.49% | - | - | - | - |
| Debt / Equity | - | 0.01x | 0.00x | - | 0.00x |
| Interest Coverage | -8872.86x | -123421.28x | - | - | - |
| FCF Conversion | 1.46x | 0.98x | 0.84x | 1.00x | 0.91x |
| Revenue Growth | - | -100% | - | - | - |
KTTA Frequently Asked Questions
Pasithea Therapeutics Corp. (KTTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pasithea Therapeutics Corp. (KTTA) grew revenue by 0.0% over the past year. Growth has been modest.
Pasithea Therapeutics Corp. (KTTA) reported a net loss of $13.5M for fiscal year 2024.
Dividend & Returns
Pasithea Therapeutics Corp. (KTTA) has a return on equity (ROE) of -72.8%. Negative ROE indicates the company is unprofitable.
Pasithea Therapeutics Corp. (KTTA) had negative free cash flow of $12.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More KTTA
Pasithea Therapeutics Corp. (KTTA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates